Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217776 | 0.76 | KDM4E (0.40) | ADRB2ADRB1ADRB3RAB9ANPC1 | |
| SCHEMBL4743256 | 0.74 | TP53 (0.54) | RAB9ANPC1ALDH1A1LMNAPOLB | |
| SCHEMBL11835830 | 0.73 | MEN1 (0.61) | ADRB2ADRB1ADRB3RAB9ANPC1 | |
| SCHEMBL12561522 | 0.71 | NPC1 (0.51) | RAB9ANPC1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL14310604 | 0.71 | RAB9A (0.54) | RAB9ANPC1TSHRALDH1A1LMNA | |
| SCHEMBL13342377 | 0.70 | NPC1 (0.50) | ADRB2ADRB1ADRB3RAB9ANPC1 | |
| SCHEMBL11321089 | 0.69 | NPC1 (0.49) | RAB9ANPC1LMNAL3MBTL1TP53 | |
| SCHEMBL4044947 | 0.68 | NPC1 (0.42) | ADRB2ADRB1ADRB3RAB9ANPC1 | |
| SCHEMBL4044952 | 0.68 | RAB9A (0.37) | ADRB2ADRB1ADRB3RAB9ANPC1 | |
| SCHEMBL6246089 | 0.68 | CSNK1D (0.44) | ADRB2ADRB1ADRB3RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1885719-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1833823-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069740-A1 | 2, 5 AND 2, 6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006066795-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060142570-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1674466-A1 | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors | 4SC AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1674467-A1 | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors | 4SC AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20060135782-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142570-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | ADRB2 578/4885ADRB1 858/4885ADRB3 194/4885 |
| US-20060135782-A1 | Benzazole analogues and uses thereof | DCK, SBK3, DAPK3 | ADRB2 3093/4885ADRB1 3625/4885ADRB3 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.